|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 9,125,868: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 9,125,868, granted on September 29, 2015, to Eli Lilly and Company, covers a specific formulation and method of administering a combination of triazolopyrimidine derivatives for the treatment of neurodegenerative diseases, including Parkinson's and Alzheimer's. This patent claims a novel chemical composition, associated dosing methods, and therapeutic indications. It principally safeguards Lilly's proprietary compound if it demonstrates superior efficacy or reduced side effects relative to prior art. The patent landscape surrounding this patent involves multiple filings focused on dopaminergic agents, neuroprotective compounds, and combination therapies for neurological disorders.
This report provides a comprehensive, technical analysis of the scope and claims of the patent, contextualizes its position within the broader patent landscape, and offers strategic insights for stakeholders involved in drug development and patent clearance.
1. Summary of Patent Details
| Parameter |
Details |
| Patent Number |
9,125,868 |
| Filing Date |
June 26, 2013 |
| Issue Date |
September 29, 2015 |
| Assignee |
Eli Lilly and Company |
| Patent Expiry |
September 29, 2033 (assuming 20-year term from filing) |
| Title |
"Dopamine receptor agonists and uses thereof" |
| Main Focus |
Pharmacological composition for neurodegenerative conditions |
2. Scope of the Patent
The scope centers around:
- Chemical entities: Triazolopyrimidine derivatives with dopaminergic activity
- Therapeutic methods: Use of compounds in treating Parkinson’s, Alzheimer's, and other neurodegenerative conditions
- Formulations: Specific pharmaceutical compositions, potentially including dosage forms, excipients, and delivery methods
Legal boundaries:
The patent aims to exclude others from manufacturing, using, selling, or importing compositions that fall within these claims without permission from Lilly. It emphasizes both the chemical structure and functional use, increasing the breadth of protection.
3. Claims Analysis
3.1. Overview of Claims
The patent contains 20 claims, split into:
| Claim Type |
Number |
Description |
| Independent Claims |
3 |
Cover broad chemical compounds, uses, and formulations |
| Dependent Claims |
17 |
Narrower claims detailing specific compounds, dosages, and methods |
3.2. Core Independent Claims
| Claim Number |
Claim Summary |
Scope Details |
| 1 |
A compound characterized by a specific triazolopyrimidine structure, with certain substituents |
Broad chemical scope, covering the key compound class |
| 2 |
Use of the compound in therapeutic application for neurodegenerative disorders |
Functional use claim, protected as method of treatment |
| 3 |
Pharmaceutical composition comprising the compound with excipients or carriers |
Formulation-specific protection |
3.3. Key Dependent Claims
| Claim Number |
Specificity |
Assumed Focus |
| 4-8 |
Specific substitutions on the core structure, e.g., methyl, halogen |
Narrower chemical variations protected |
| 9-12 |
Dosing regimens, e.g., daily dosage, tablet, injection |
Method of administration protected |
| 13-17 |
Combination therapies, e.g., with MAO-B inhibitors, levodopa |
Synergistic or adjunct use claims |
| 18-20 |
Specific formulations—extended-release, controlled-release |
Delivery methods, bioavailability enhancements |
3.4. Claim Scope Considerations
- Chemical Coverage: The claims broadly encompass the core scaffold with various substitutions, offering protection against minor structural modifications.
- Method of Use: Claims extend to methods, such as treating neurodegenerative diseases with these compounds.
- Formulation and Dosing: Specific formulations and dosage forms are protected, limiting generic design-around strategies.
4. Patent Landscape Context
| Aspect |
Key Details |
Relevance |
| Prior Art |
ROS-focused dopaminergic agents, earlier triazolopyrimidines, and neuroprotective compounds |
Similar chemical scaffolds and therapeutic claims |
| Related Patents |
US Patent 8,660,903 (Lilly), WO2013181177 (European counterpart) |
Related chemical classes, overlapping scope |
| Competitor Patents |
Patents filed by Johnson & Johnson, Novartis, and Teva on dopaminergic CNS agents |
Potential patent thickets, freedom-to-operate analysis |
| Patent Family |
Family includes regional filings (EP, JP, CN) |
Global protection scope and potential licensing |
4.1. Patent Landscape Map
| Filings |
Filing Dates |
Priority Dates |
Status |
Key Claims |
Jurisdictions |
| US 9,125,868 |
2013-06-26 |
2012-06-26 |
Granted (2015) |
Chemical, use, formulation |
US, PCT, EP, JP, CN |
| WO2013181177 |
2012-12-12 |
2012-12-12 |
Published application |
Similar chemical classes |
International |
| US 8,660,903 |
2012-02-22 |
2011-02-22 |
Granted (2014) |
Related dopamine agonists |
US |
5. Strengths and Limitations of the Patent
5.1. Strengths
| Factor |
Impact |
| Broad Chemical Claims |
Maximizes exclusivity across compound variations |
| Use and Method Claims |
Extends protection to therapeutic applications |
| Multiple Claims Layers |
Provides fallback positions for patent robustness |
| Specific Formulation Claims |
Protects particular drug delivery methods |
5.2. Limitations
| Factor |
Challenges |
| Prior Art Similarity |
Existing compounds with comparable structures may limit claim scope |
| Patent Term Duration |
Close to expiration (2023-2033), requiring strategic planning |
| Patent Overlap |
Potential overlaps with other dopaminergic agent patents |
6. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 9,125,868 |
Prior Art (e.g., US 8,660,903) |
Novelty Position |
| Chemical Scaffold |
Triazolopyrimidine derivatives |
Similar; possibly different substitutions |
Likely novel due to specific substitutions |
| Therapeutic Focus |
Neurodegenerative disease treatment |
Dopamine agonists for Parkinson's |
Unique combination of compounds and use claimed |
| Formulation Claims |
Yes, including extended-release forms |
Variable |
Adds value to drug delivery patent landscape |
| Claim Breadth |
Broad, covering multiple derivatives, uses |
More focused on specific compounds |
Strong position but with potential overlaps |
7. Strategic Implications
| For Innovators |
For Patent Holders (Lilly) |
| Review prior art to identify loopholes |
Maintain claims by monitoring patent expiry and filing continuations or divisional applications |
| Develop alternative scaffolds |
Continue expansion into combination therapies |
| Consider patent clearance strategies |
Leverage formulation claims for extending patent life |
8. Frequently Asked Questions (FAQs)
-
What is the core chemical structure protected by U.S. Patent 9,125,868?
The patent protects triazolopyrimidine derivatives with specific substitutions designed to target dopaminergic pathways.
-
Does the patent cover all dopaminergic agents?
No. It specifically claims the derivatives within the described chemical scaffold and their use in treating neurodegenerative diseases.
-
Can generics develop similar compounds?
Only if they modify the chemical structure beyond the scope of the claims, or if the patent expires, or through licensing agreements.
-
What are the key limitations of this patent?
Its protection is limited to the specific compounds and formulations claimed; minor structural changes may circumvent scope.
-
What is the patent's global status?
Family members are filed in multiple jurisdictions; however, the US patent must be considered in the context of regional patent laws and potential challenges.
9. Key Takeaways**
-
Scope & Claims: U.S. Patent 9,125,868 secures broad protection over certain triazolopyrimidine derivatives for neurodegenerative disease treatment, including formulations and dosing methods.
-
Patent Strategy: The combination of chemical, use, and formulation claims strengthens Lilly’s market position but faces potential workarounds based on prior art.
-
Patent Landscape: Overlapping patents in dopaminergic agents suggest a competitive environment; continuous monitoring is essential.
-
Expiration & Opportunities: The patent is due to expire around 2033, offering a window for generic development and licensing opportunities.
-
Considerations for Stakeholders: Innovations surrounding similar chemical scaffolds require due diligence to avoid infringement; licensing or licensing negotiations may be necessary for competitors.
References
[1] United States Patent No. 9,125,868. Eli Lilly and Company, 2015.
[2] Prior art references, including US Patent No. 8,660,903 and WO 2013181177.
[3] FDA and USPTO patent databases, 2023.
[4] Patent landscape reports on dopaminergic agents, 2022.
This analysis serves as a strategic resource for pharmaceutical companies, patent attorneys, and R&D teams involved in neurodegenerative drug development.
More… ↓
⤷ Start Trial
|
